Thank you for sitting down with us, Brad. Let’s start with an overview: What is the current focus for Endexx, and how does HYLA play a role in that?
Brad Listermann: Absolutely, thanks for having me. Right now, Endexx is heavily focused on its growth trajectory, and HYLA is truly at the forefront. We’ve chosen to focus more on HYLA for the time being, as we see incredible potential in its expanding international market and growing customer loyalty. Of course, we’re grateful for CBD Unlimited, which paved the way for us and opened doors to get us to this point, but our primary resources and energy are going into HYLA’s development.
Impressive! Can you clarify how HYLA is performing internationally, especially regarding market expansion?
Brad Listermann: Certainly. HYLA’s distribution network now spans a total of 10 countries, with nine of these markets being new additions just in the latter half of this year. This expansion includes new deals with established distribution partners in each of these countries, ensuring that we’re not only broadening our reach but doing so with sustainable partnerships. Reorders are already coming in from a majority of these partners, which is a strong indicator of product-market fit.
With such growth, is HYLA contributing to Endexx’s bottom line as expected?
Brad Listermann: Yes, absolutely. HYLA is already one of our strongest revenue sources, and the potential for growth is huge. We’re also excited about some new product lines that we’ll be introducing soon. For instance, HYLA Pouches—these are nicotine-free pouches aimed at two expanding markets: natural energy and relaxation. Imagine a pouch you can use for a quick boost or to wind down in the evening. This market is exploding, and we plan to be a major player within it.
How does distribution fit into this expansion? Are you exploring new channels?
Brad Listermann: Distribution is key, and I’m thrilled with the progress our team is making. Dustin Sullivan is leading our U.S. distribution strategy, and we recently announced a major distribution agreement with American Shaman. That’s just the beginning of what we’re planning for U.S. partnerships. Nick Mehdi, as HYLA’s president, is spearheading our international expansion, helping us bring HYLA into multiple new markets globally. We’re also focused on U.S. retail partnerships and distribution with significant potential. If these discussions go well, they could materialize by year-end, which would be a big win for us.
Brad, some investors have expressed concerns about Endexx no longer being a fully reporting SEC company. Can you tell us more about your plans for getting back to that status?
Brad Listermann: Absolutely, that’s a priority for us, and we’re moving in that direction. Right now, we’re working with our selected auditor, Victor Mokuolu, CPA PLLC (VMCPA). Doug Williams, our fractional CFO, and I are collaborating closely with VMCPA to prepare for an audit, which we anticipate will happen in the near future. While we aim to be fully reporting by early next year, the exact start date may shift slightly depending on the preparation timeline. For us, the focus is on ensuring we do this right and on making Endexx lean and fiscally responsible as we move forward.
Speaking of growth and brand identity, there have been mentions of rebranding efforts. Could you give us an update on that, and what can shareholders expect?
Brad Listermann: Certainly. Rebranding is part of our evolution as HYLA continues to play a larger role within Endexx. We’re aligning everything—from product packaging to our online presence—to reflect our commitment to wellness and non-nicotine products. This transition also includes updating our ticker to better represent our vision and brand, creating stronger recognition in the marketplace and attracting more investors aligned with our wellness-focused mission.
Exciting developments, Brad. What are the next steps as you close out the year?
Brad Listermann: We’re focused on maintaining this growth trajectory, enhancing our distribution channels, and expanding in high-margin online sales. With new deals lined up, recurring orders increasing, and a firm rebranding underway, we’re positioned for a strong close to the year and a promising start to the next. This momentum sets a solid foundation as we advance our long-term goals.
Thank you, Brad, for the insights and a promising outlook for Endexx and HYLA. Endexx is publicly traded on the OTC Markets as EDXC.
More on Endexx and HYLA distribution opportunities at: hyladistribution.com and endexx.com